NCT05718817
An Open-label Study of XEN1101 in Epilepsy
Enrolling by Invitation
PHASE3Ages 12+InterventionalTreatmentXenon Pharmaceuticals Inc.
~880 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:XEN1101
At a glance
Recruiting sites
0 of 151 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The adverse events
Measured over From the start of treatment in the open-label extension (OLE) study through 8 weeks after the last dose.
Conditions
Where it's being run
151 sites across 57 statesArgentina12
Spain10
Australia8
Germany7
Portugal7
Florida6
Poland6
New York5
Study leadership
- Medical Director · STUDY_DIRECTOR · Xenon Pharmaceuticals Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- The adverse eventsFrom the start of treatment in the open-label extension (OLE) study through 8 weeks after the last dose.
To assess the safety and tolerability of XEN1101